FDA approves for the activL artificial disc for one-level lumbar use

By

Aesculap Receives FDA Approval for the activL® Artificial Disc for One-Level Lumbar Use (press release)
Intelligent Motion Technology for Total Disc Replacement; activL Is Designed as an Alternative to Spinal Fusion Surgery to Allow Motion at the Treated Level of the Lower Back
Aesculap Implant Systems, LLC (Aesculap), a privately held medical device company, announced today that it has received a letter of approval from the U.S. Food and Drug Administration (FDA) allowing the commercial sale of the activL® Artificial Disc, for the treatment of one-level lumbar degenerative disc disease.
Chuck...

Get access to full posts newsletters, trends, and market reports for only subscribe for $1/day.
Hit the SUBSCRIBE button at the top of the homepage.